Anti-CD123 monoclonal antibody CPI conjugate(Pfizer)

N/A

Report date: 2026/01/26 17:58:59

Base Information

Drug NameAnti-CD123 monoclonal antibody CPI conjugate(Pfizer)
Drug Alias NameCD123-ADCAnti-CD123-CPIanti-CD123-ADC
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionDNA inhibitorsAlkylating agentsAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Holding France Farevaamboise
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Holding France Farevaamboise
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A